Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma. - Wikidata - awgldk - TriplyDB

Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma.

Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma.

http://www.wikidata.org/entity/Q36758735

about

Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New Biomarker development in MET-targeted therapy Platelet-derived growth factor receptor/platelet-derived growth factor (PDGFR/PDGF) system is a prognostic and treatment response biomarker with multifarious therapeutic targets in cancers.MICA/B expression is inhibited by unfolded protein response and associated with poor prognosis in human hepatocellular carcinoma.The c-Met Inhibitor MSC2156119J Effectively Inhibits Tumor Growth in Liver Cancer Models Autophagy inhibition sensitizes hepatocellular carcinoma to the multikinase inhibitor linifanib.Redundant kinase activation and resistance of EGFR-tyrosine kinase inhibitors.DNA methylation, microRNAs, and their crosstalk as potential biomarkers in hepatocellular carcinoma.Reciprocal activating crosstalk between c-Met and caveolin 1 promotes invasive phenotype in hepatocellular carcinoma.Sorafenib and DE605, a novel c-Met inhibitor, synergistically suppress hepatocellular carcinoma.Bioinformatics approach to predict target genes for dysregulated microRNAs in hepatocellular carcinoma: study on a chemically-induced HCC mouse model.Tivantinib induces G2/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinoma.c-MET expression in colorectal adenomas and primary carcinomas with its corresponding metastases Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in mice.Overexpression of CTNND1 in hepatocellular carcinoma promotes carcinous characters through activation of Wnt/β-catenin signaling Hepatic stellate cell promoted hepatoma cell invasion via the HGF/c-Met signaling pathway regulated by p53 Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group.Treating advanced hepatocellular carcinoma: How to get out of first gear.Effects and Mechanism of Imatinib in Inhibiting Colon Cancer Cell Proliferation Advanced Hepatocellular Cancer: the Current State of Future Research.Inhibition of Hec1 as a novel approach for treatment of primary liver cancer.Gender disparity in hepatocellular carcinoma (HCC): multiple underlying mechanisms.Potentiation of doxorubicin efficacy in hepatocellular carcinoma by the DNA repair inhibitor DT01 in preclinical models.Optical Imaging of Mesenchymal Epithelial Transition Factor (MET) for Enhanced Detection and Characterization of Primary and Metastatic Hepatic Tumors High expression of PDGFR-β in prostate cancer stroma is independently associated with clinical and biochemical prostate cancer recurrence Antiangiogenic agents after first line and sorafenib plus chemoembolization: a systematic review.Interferon Regulatory Factor 5 (IRF5) suppresses Hepatitis C Virus (HCV) Replication and HCV-Associated Hepatocellular Carcinoma.Pretreatment MicroRNA Level and Outcome in Sorafenib-treated Hepatocellular Carcinoma.Prognostic value of c-Met overexpression in hepatocellular carcinoma: a meta-analysis and review.Involvement of platelet-derived growth factor ligands and receptors in tumorigenesis.A Novel Diagnostic Tool for Selecting Patients With Mesenchymal-Type Colon Cancer Reveals Intratumor Subtype Heterogeneity.MET is a predictive factor for late recurrence but not for overall survival of early stage hepatocellular carcinoma.Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?

P2860

Q26744542-870E5D3C-63F1-4E05-8D32-804E4069C172 Q26751332-A386D9FA-0E19-4F06-96BD-5BCFFEC9B5DC Q30250273-DE629196-5126-4C61-949D-1AA6C2D6B5FD Q34241771-0300D30E-DE44-4D5F-9FC6-377EE7D07996 Q34309954-814F36F8-7593-454C-9CCC-680DB10B820B Q34366102-79F0A549-DF03-48BA-A5CD-BBA26227F8E8 Q34704781-712076E5-CA88-47AD-9E27-D33F8A13A477 Q35197356-53FFA323-AFB8-4FF3-A428-CED37C3BCA71 Q35229808-C53E6755-2CC5-43B9-BA6F-3A4EC6245A20 Q35828564-4EE59902-8B9E-48E4-B02B-E0156D3BE872 Q35865032-E17D70AC-92A6-43A8-8448-CA4AE2C9F8C2 Q36156854-8911484D-120C-4E64-864E-2593959414BC Q36352462-20DBFB20-65CB-4530-9BC8-EB47110C26E5 Q36560210-111AA802-4521-4D2B-967C-2BD63F7081CB Q36915235-3F42DFD2-0DBA-426C-B8B2-CA7325712ABD Q36957055-9958A3C1-A283-4538-98F6-61F28754E264 Q37046852-DC6FC332-F11F-45FE-8DE4-57AEE2F37DA4 Q38217737-2AFA8A7B-F347-46DD-AA99-EDB8EDCD9938 Q38734640-D154FB5E-9CD7-409C-B74E-1C2B0CAF1DDA Q38848537-FA7F3C0A-A4E9-41FE-84AC-D3976562ABAA Q38974099-2A7CE646-9A1A-47DA-BE20-9C216B6D5D4A Q39332017-32E9F6B6-E217-47F7-874E-55B80178C655 Q40259741-69526AC1-0CAA-4AC7-B508-A60BC5E9A71B Q40555550-B090276F-69B3-45F7-887A-2DB20C8A5E9F Q41967756-9DBFD54D-2BC5-4FA3-81E8-B80EFA742B42 Q42371684-BFC5E227-6FC5-41BD-8F04-A7AFE24664BC Q45325557-9C4116F7-AD4A-4BF5-A0AF-39C120A21D33 Q46124376-B91CBEC4-43F3-455F-81AF-468DE3575D84 Q47139946-F402738D-D04D-4DE2-B370-A5075177B8D7 Q47756210-5F48E748-6139-4884-826B-35A32B0C63FA Q51071981-288A9513-3977-4B9F-8CA0-7D1E8DA5694B Q54277972-022F2BBD-F9D3-4BCC-BA56-FDFF78CB8CE2 Q57067866-4A5AB525-20DF-4989-AF04-BD186C4ED545

P2860

Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma.

http://www.wikidata.org/entity/Q36758735

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Expression and prognostic valu ...... nced hepatocellular carcinoma.

@ast

Expression and prognostic valu ...... nced hepatocellular carcinoma.

@en

type

label

Expression and prognostic valu ...... nced hepatocellular carcinoma.

@ast

Expression and prognostic valu ...... nced hepatocellular carcinoma.

@en

prefLabel

Expression and prognostic valu ...... nced hepatocellular carcinoma.

@ast

Expression and prognostic valu ...... nced hepatocellular carcinoma.

@en

P1433

Q36758735-B13D7F92-58D9-4879-8ACF-5D06BA2E8C67

P1476

Q36758735-C177E884-7C98-421F-B908-294577865413

P2093

Q36758735-28C2B9A7-F809-45A6-951E-991D1F5C78AF

Q36758735-2ED558D3-7694-4E53-A2F4-29F2BCB012B9

Q36758735-46B0F4AF-CDE8-4DE0-B8ED-C9269196D3E7

Q36758735-4795FE8D-B570-43F3-9477-4581DE2586BF

Q36758735-4B31B3A5-5884-4DCE-84E6-BDC9A2260B68

Q36758735-6A7B4DC8-5803-4821-B02A-D3389C8EA08F

Q36758735-797E9BCF-271F-4FC0-838D-ADEA3688B402

Q36758735-7D0A7CB4-DB6C-436A-91BC-BCD0A5933E44

Q36758735-7DEB2862-0AD6-490F-A760-45EC0562C90C

Q36758735-7F3CC10B-BCBC-4F5A-A18C-25DC03CCD2D4

P2860

Q36758735-00930097-1C74-4A65-8A76-268A46A23653

Q36758735-02644536-04D7-450C-A6A9-5940F0629B77

Q36758735-27E1BF78-DD01-48F0-A8C4-676FE169DE06

Q36758735-280B7458-B313-4F7E-A880-C7E690493894

Q36758735-2BD447BE-6DD2-4A90-AE83-D1D828BD7FC4

Q36758735-2FB6545F-B66B-457B-946B-918BC2D302CA

Q36758735-4CF6E19E-6C4E-477B-BD1C-7B99C4A7C137

Q36758735-5930ED96-1ACB-47FF-84D9-F34D6D2A7B6E

Q36758735-6D0A7CF3-FACE-48C4-AF42-7C14EEEE7064

Q36758735-83B3B073-9930-4E70-BC63-B1ABF5C5B1F3

P2888

Q36758735-1832C9B7-5681-48FA-9B29-0002561031EE

P304

Q36758735-577C24FE-86B0-42F9-9C38-5BB1052E340E

P31

Q36758735-30A25F14-1AE6-4B71-AA3A-FCBC730C4E85

P356

Q36758735-6733ED77-1BE1-4324-A21F-A37794925BDE

P478

Q36758735-BE4486AA-2905-40ED-B480-A1C54A1EC16F

P577

Q36758735-AF21E7D4-5489-4572-8624-62C3C538FEAB

P5875

Q36758735-3AC9F25D-845E-4F48-AEBB-782EF2ACF9B3

P6179

Q36758735-95932ADD-3A45-47BE-9BB0-E4AFEF95B769

P698

Q36758735-B0E23FD7-746D-4F35-B40B-E6E26F0E1D65

P932

Q36758735-ADF0F60F-F85E-4E72-8D49-B68D84B7CDCF

P356

1756-9966-32-16

P1433

Journal of Experimental & Clinical Cancer Research

P1476

Expression and prognostic valu ...... nced hepatocellular carcinoma.

@en

P2093

Angelo Paradiso

http://www.w3.org/2001/XMLSchema#string

Anna Elisabetta Brunetti

http://www.w3.org/2001/XMLSchema#string

Bo Zhang

http://www.w3.org/2001/XMLSchema#string

Chuan Hua Zhao

http://www.w3.org/2001/XMLSchema#string

Fei Jiao Ge

http://www.w3.org/2001/XMLSchema#string

Jian Ming Xu

http://www.w3.org/2001/XMLSchema#string

Jie Sheng Chu

http://www.w3.org/2001/XMLSchema#string

Jun Wang

http://www.w3.org/2001/XMLSchema#string

Li Lin

http://www.w3.org/2001/XMLSchema#string

Lie Jun Liu

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics, 2002

Sorafenib in advanced hepatocellular carcinoma

Hepatocellular carcinoma: epidemiology and molecular carcinogenesis

Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Drug development of MET inhibitors: targeting oncogene addiction and expedience.

A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors.

Hepatitis B x antigen up-regulates vascular endothelial growth factor receptor 3 in hepatocarcinogenesis.

Sinusoidal obstruction syndrome (veno-occlusive disease) in the rat is prevented by matrix metalloproteinase inhibition.

Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib.

P2888

1756-9966-32-16

P304

16

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1756-9966-32-16

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P577

2013-04-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236103508

http://www.w3.org/2001/XMLSchema#string

P6179

1033506449

http://www.w3.org/2001/XMLSchema#string

P698

23552472

http://www.w3.org/2001/XMLSchema#string

P932

3623756

http://www.w3.org/2001/XMLSchema#string